{'fraction_non_alphanumeric': 0.035547785547785545, 'fraction_numerical': 0.007575757575757576, 'mean_word_length': 5.479245283018868, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Ultrasensitive photoelectrochemical immunoassay for prostate-specific antigen based on silver nanoparticle-triggered ion-exchange reaction with ZnO/CdS nanorods.

Prostate-specific antigen (PSA), a glycoprotein that is most likely to cause prostate cancer, has attracted widespread attention in recent years due to its increasing threat to people's lives and health. Herein, we developed a new signal-amplified photoelectrochemical (PEC) immunosensing method for quantitative monitoring of the target PSA based on the ion-exchange reaction for the in situ formation of ZnO/CdS/Ag2S nanohybrids triggered by the as-released silver ions (Ag+) from silver nanolabels. Initially, the introduction of a target PSA caused the formation of a sandwich immunocomplex in an anti-PSA capture antibody (cAb)-coated microplate with the help of a silver nanoparticle-labeled detection antibody (AgNPs-dAb). Thereafter, the introduced AgNPs were dissolved with acid to release numerous silver ions. In this regard, an ion-exchange reaction occurred between the silver ions and ZnO/CdS nanorods on the photosensitive electrode, thus producing ZnO/CdS/Ag2S nanohybrids to generate a relatively strong photocurrent. Under optimal conditions, the ion-exchange reaction-based PEC immunoassay exhibited a good linear range of 0.05-50 ng mL-1 and allowed the detection of the target PSA at a concentration as low as 0.018 ng mL-1. In addition, the PEC immunoassay displayed satisfactory repeatability, high specificity, and acceptable method accuracy. Importantly, the ion-exchange reaction-based PEC immunoassay provides a new perspective for the detection of other disease-related biomarkers by controlling the corresponding antibodies.